Latest Breaking News On - Digestive disease - Page 1 : vimarsana.com

Weight gain during diet therapy linked to 'worse EoE outcomes' no matter baseline weight

WASHINGTON — Among adults with eosinophilic esophagitis, weight gain while undergoing dietary therapy was associated with poor treatment response, regardless of baseline weight status, according to data presented at Digestive Disease Week. “EoE prevalence has increased alongside the obesity epidemic,” Stephanie A. Borinsky, MD, a gastroenterology fellow in the department of

Evogene Ltd. (NASDAQ:EVGN) Q1 2024 Earnings Call Transcript

'Unexpectedly high' placebo response derails darvadstrocel for Crohn's perianal fistulas

Dr Ajay Goel Explains How Liquid Biopsies Can Be Used in Future Care of CRC

Clinical use of liquid biopsies to determine the likelihood of CRC is the goal based on its effectiveness in recent studies.

'Make it a priority': #YourDigestiveHealth campaign spotlights key role in quality of life

To celebrate World Digestive Health Day on May 29, the World Gastroenterology Organization launched a campaign, “Your Digestive Health: Make It A Priority,” to boost awareness on the vital role the digestive system plays in overall health.The public advocacy campaign focuses on the importance of prioritizing digestive health to maintain quality of life and overall wellbeing and, by

Anthony Lembo, MD: Exploring Probiotics for IBS Treatment

Lembo describes the potential of a multi-species synbiotic for the treatment of IBS based on findings from an exploratory study he presented at DDW.

Dr Ajay Goel Discusses Future of MicroRNAs in CRC Prognosis, Treatment

MicroRNAs could be a key to future testing for colorectal cancer (CRC) and determining treatment.

Endoscopic, histologic improvements in EoE sustained at 52 weeks with etrasimod

WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data. “Etrasimod is a an oral, once-daily selective sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active

Prevalence of advanced fibrosis similar in lean, non-lean MASLD, linked to genetic risk

WASHINGTON — The risk for advanced fibrosis was similar among patients with lean and non-lean metabolic dysfunction-associated steatotic liver disease and may be associated with genetic risk, according to data at Digestive Disease Week. “There are conflicting studies on the severity of MASLD in patients with a normal BMI, termed lean MASLD, which is estimated to affect up to 10

Dr Ajay Goel Discusses New Methods of Testing for EOCRC, Recurrence

Ajay Goel, PhD, AGAF, explains the significance of 2 new studies that found that early-onset colorectal cancer (EOCRC) and recurrence in CRC could both be predicted using new blood and tissue tests.